94
Views
4
CrossRef citations to date
0
Altmetric
Research Articles

Hepatoprotective effects of Psidium guajava on mitochondrial enzymes and inflammatory markers in carbon tetrachloride-induced hepatotoxicity

, , , , , , ORCID Icon & show all
Pages 2041-2050 | Received 25 Apr 2020, Accepted 24 Oct 2020, Published online: 20 Nov 2020
 

Abstract

Objective

The present investigation was aimed to evaluate the hepatoprotective potential of ethanolic extract of Psidium guajava (P. guajva) and its isolated quercetin fraction on carbon tetrachloride (CCl4)-induced hepatotoxicity.

Materials and methods

The rats were divided into 6 groups and each group contained 6 rats. CCl4 (1.5 ml/kg b.w.) was used to induce the hepatotoxicity. Ethanolic extract of P. guajava (300 mg/kg b.w.), isolated quercetin fraction (20 mg/kg b.w.) were used as a treatment and silymarin (25 mg/kg b.w.) was used as a standard drug. After the study period, the liver tissues were collected and evaluate the levels of liver functional markers, mitochondrial enzymes, histopathological analysis and the expressions of inflammatory markers.

Results

The levels of liver functional markers were increased and protein, albumin and A/G ratio levels were decreased and the decreased levels of mitochondrial enzymes were noted in CCl4-induced rats and the levels were restored near to normal significantly when the administration ethanolic extract of P. guajava, isolated quercetin fraction and silymarin. The normal architecture of liver tissues were altered and the mRNA expressions were up-regulated in CCl4-induced rats and the liver tissues were normalized and the mRNA and protein expressions were down-regulated near to normal significantly when the administration of ethanolic extract of P. guajava, isolated quercetin fraction and silymarin.

Conclusion

From these results, the isolated quercetin fractions have better activity than that of the ethanolic extract of P. guajava leaves. Hence, the isolated quercetin may be used as the safest drug for hepatotoxicity in future.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.